第 1 到 8 筆結果,共 8 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2019 | Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression | Yeo W.; Ueno T.; CHING-HUNG LIN ; Liu Q.; Lee K.-H.; Leung R.; Naito Y.; Park Y.H.; Im S.-A.; Li H.; Yap Y.S.; YEN-SHEN LU ; The Asian Breast Cancer Cooperative Group | Breast Cancer Research and Treatment | 29 | 27 | |
2 | 2004 | Recent advances in the management of primary breast cancers | YEN-SHEN LU ; SUNG-HSIN KUO ; CHIUN-SHENG HUANG | Journal of the Formosan Medical Association | 15 | 14 | |
3 | 2010 | The prevalence and assessment of ErbB2-positive breast cancer in Asia: A literature survey | Tan Y.O; Han S; YEN-SHEN LU ; Yip C.-H; Sunpaweravong P; Jeong J; Caguioa P.B; Aggarwal S; Yeoh E.M; Moon H. | Cancer | 17 | 16 | |
4 | 2021 | An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer | YEN-SHEN LU ; Yeo W.; Yap Y.-S.; Park Y.H.; Tamura K.; Li H.; Cheng R. | Targeted Oncology | 5 | 5 | |
5 | 2021 | Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women | YEN-SHEN LU ; Wong A.; Kim H.-J. | Frontiers in Oncology | 9 | 8 | |
6 | 2009 | Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009 | Wong N.S; Anderson B.O; Khoo K.S; Ang P.T; Yip C.H; YEN-SHEN LU ; Voravud N; Shao Z.-M; Pritchard K.I. | The Lancet Oncology | 25 | 24 | |
7 | 2010 | Management of ErbB2-positive breast cancer: Insights from preclinical and clinical studies with lapatinib | Vogel C; Chan A; Gril B; Kim S.-B; Kurebayashi J; Liu L; YEN-SHEN LU ; Moon H. | Japanese Journal of Clinical Oncology | 21 | 19 | |
8 | 2019 | Insights into Breast Cancer in the East vs the West: A Review | Yap Y.-S.; YEN-SHEN LU ; Tamura K.; Lee J.E.; Ko E.Y.; Park Y.H.; Cao A.-Y.; CHING-HUNG LIN ; Toi M.; Wu J.; Lee S.-C. | JAMA Oncology | 87 | 66 |